• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Rev Microbiol . SARS-CoV-2 variants, spike mutations and immune escape

tetano

Editor, Senior Moderator
Nat Rev Microbiol


. 2021 Jun 1.
doi: 10.1038/s41579-021-00573-0. Online ahead of print.
SARS-CoV-2 variants, spike mutations and immune escape


William T Harvey[SUP] #[/SUP][SUP] 1 2 [/SUP], Alessandro M Carabelli[SUP] #[/SUP][SUP] 3 [/SUP], Ben Jackson[SUP] 4 [/SUP], Ravindra K Gupta[SUP] 5 [/SUP], Emma C Thomson[SUP] 6 7 [/SUP], Ewan M Harrison[SUP] 3 7 [/SUP], Catherine Ludden[SUP] 3 [/SUP], Richard Reeve[SUP] 1 [/SUP], Andrew Rambaut[SUP] 4 [/SUP], COVID-19 Genomics UK (COG-UK) Consortium; Sharon J Peacock[SUP] 3 [/SUP], David L Robertson[SUP] 8 [/SUP]



Affiliations

Abstract

Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome are expected to be either deleterious and swiftly purged or relatively neutral, a small proportion will affect functional properties and may alter infectivity, disease severity or interactions with host immunity. The emergence of SARS-CoV-2 in late 2019 was followed by a period of relative evolutionary stasis lasting about 11 months. Since late 2020, however, SARS-CoV-2 evolution has been characterized by the emergence of sets of mutations, in the context of 'variants of concern', that impact virus characteristics, including transmissibility and antigenicity, probably in response to the changing immune profile of the human population. There is emerging evidence of reduced neutralization of some SARS-CoV-2 variants by postvaccination serum; however, a greater understanding of correlates of protection is required to evaluate how this may impact vaccine effectiveness. Nonetheless, manufacturers are preparing platforms for a possible update of vaccine sequences, and it is crucial that surveillance of genetic and antigenic changes in the global virus population is done alongside experiments to elucidate the phenotypic impacts of mutations. In this Review, we summarize the literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discuss them in the context of observed mutation frequencies in global sequence datasets.
 
Back
Top Bottom